Due to various limitations associated with the use of DCs as vaccines, mature DCs have been developed in vitro and employed as cancer vaccines because they can effectively produce tumor-specific antigens for recognition by CD4+ and CD8+ T cells. Here, CD8A is linked to neoplasm.